Bionomics Posts Positive Data In PTSD With Struggling Anxiety Drug
After failing in a Phase II trial in social anxiety disorder, Bionomics thinks mid-stage data for BNC210 in post-traumatic stress disorder may now position the drug as a novel therapy for PTSD.
You may also be interested in...
Public Company Edition: Genenta, Cingulate, ImmixBio, Bionomics and NeuroSense launched initial public offerings, grossing just $118m between them. But Amylyx, with a recently filed ALS drug, has filed to raise up to $100m. In follow-on offerings, Legend took advantage of ASH goodwill to raise $300m.
Tonix Pharmaceuticals’ sublingual cyclobenzaprine has failed to show better efficacy than placebo in an interim analysis of the Phase III RECOVERY trial in post-traumatic stress disorder patients, although the study will continue to completion in already-enrolled patients. The product is also in development for fibromyalgia.
Australia’s Bionomics unveils the therapeutic action of its BNC210 compound and faced shareholder questions all in one busy week for the biotech.